Literature DB >> 15251585

Recurrent hyperthyroidism after radioiodine-induced hypothyroidism: report of two cases and literature review.

G H Tan1, H Gharib.   

Abstract

The practice at the Mayo Clinic in treating Graves' disease with radioiodine (131 I) is to achieve a hypothyroid state. Less than 10% of the patients need more than one dose. Although cases of transient hypothyroidism have been reported after treatment with 131 I, the recurrence of hyperthyroidism is unusual after hypothyroidism has been induced with 131 I. We studied two cases seen at our institution in the past year in which the circumstances behind the recurrence have never been reported previously. The first case illustrates a recurrence of hyperthyroidism after the patient had received 38.5 mCi of 131 I. The second patient had recurrence of hyperthyroidism after 22 years of replacement therapy with levothyroxine. Both patients had increased levels of thyroid-stimulating immunoglobulin. We believe that the recurrence of the hyperthyroid state in these two patients was due to incomplete ablation of the thyroid. Apparently 131 I caused hypothyroidism, but residual cells remained viable and under continuous stimulation of thyroid-stimulating immunoglobulin produced recurrent thyrotoxicosis.

Entities:  

Year:  1995        PMID: 15251585     DOI: 10.4158/EP.1.3.158

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  2 in total

Review 1.  Recurrent Graves' hyperthyroidism after prolonged radioiodine-induced hypothyroidism.

Authors:  Fariha Salman; Hooman Oktaei; Solomon Solomon; Ebenezer Nyenwe
Journal:  Ther Adv Endocrinol Metab       Date:  2017-09-12       Impact factor: 3.565

2.  Extremely high doses of radioiodine required for treatment of Graves' hyperthyroidism: a case report.

Authors:  Arnaldo Moura Neto; Marcos Antonio Tambascia; Sergio Brunetto; Celso Dario Ramos; Denise Engelbrecht Zantut-Wittmann
Journal:  Cases J       Date:  2009-08-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.